Phathom Pharmaceuticals, Inc. PHAT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Phathom Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s EBITDA margin?
- Phathom Pharmaceuticals, Inc. (PHAT) reported EBITDA margin of -46.9% in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s EBITDA margin changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s EBITDA margin increased by 86.6% year-over-year, from -348.9% to -46.9%.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s EBITDA margin?
- Over 2 years (2023 to 2025), Phathom Pharmaceuticals, Inc.'s EBITDA margin has grown at a -93.9% compound annual growth rate (CAGR), from -24,448.2% to -91%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.